Literature DB >> 33045844

Polypharmacy in Older Adults Hospitalized for Heart Failure.

Ozan Unlu1, Emily B Levitan2, Evgeniya Reshetnyak3, Jerard Kneifati-Hayek4, Ivan Diaz5, Alexi Archambault3, Ligong Chen2, Joseph T Hanlon6, Mathew S Maurer7, Monika M Safford3, Mark S Lachs8, Parag Goyal3,9.   

Abstract

BACKGROUND: Despite potential harm that can result from polypharmacy, real-world data on polypharmacy in the setting of heart failure (HF) are limited. We sought to address this knowledge gap by studying older adults hospitalized for HF derived from the REGARDS study (Reasons for Geographic and Racial Differences in Stroke).
METHODS: We examined 558 older adults aged ≥65 years with adjudicated HF hospitalizations from 380 hospitals across the United States. We collected and examined data from the REGARDS baseline assessment, medical charts from HF-adjudicated hospitalizations, the American Hospital Association annual survey database, and Medicare's Hospital Compare website. We counted the number of medications taken at hospital admission and discharge; and classified each medication as HF-related, non-HF cardiovascular-related, or noncardiovascular-related.
RESULTS: The vast majority of participants (84% at admission and 95% at discharge) took ≥5 medications; and 42% at admission and 55% at discharge took ≥10 medications. The prevalence of taking ≥10 medications (polypharmacy) increased over the study period. As the number of total medications increased, the number of noncardiovascular medications increased more rapidly than the number of HF-related or non-HF cardiovascular medications.
CONCLUSIONS: Defining polypharmacy as taking ≥10 medications might be more ideal in the HF population as most patients already take ≥5 medications. Polypharmacy is common both at admission and hospital discharge, and its prevalence is rising over time. The majority of medications taken by older adults with HF are noncardiovascular medications. There is a need to develop strategies that can mitigate the negative effects of polypharmacy among older adults with HF.

Entities:  

Keywords:  heart failure; hospitalization; polypharmacy; prevalence

Mesh:

Substances:

Year:  2020        PMID: 33045844      PMCID: PMC8819498          DOI: 10.1161/CIRCHEARTFAILURE.120.006977

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  48 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

Review 3.  Pharmacotherapy of heart failure in the elderly: adverse events.

Authors:  Michael W Rich
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

4.  Potentially inappropriate medication use in elderly Japanese patients.

Authors:  Manabu Akazawa; Hirohisa Imai; Ataru Igarashi; Kiichiro Tsutani
Journal:  Am J Geriatr Pharmacother       Date:  2010-04

5.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

6.  Reply: Toward Improved Understanding of Potential Harm in Heart Failure.

Authors:  Parag Goyal; Jerard Kneifati-Hayek; Alexi Archambault; Krisha Mehta; Emily B Levitan; Ligong Chen; Ivan Diaz; James Hollenberg; Joseph T Hanlon; Mark S Lachs; Mathew S Maurer; Monika M Safford
Journal:  JACC Heart Fail       Date:  2020-03       Impact factor: 12.035

7.  Polypharmacy in the Elderly: A Marker of Increased Risk of Mortality in a Population-Based Prospective Study (NEDICES).

Authors:  Candelas Gómez; Saturio Vega-Quiroga; Félix Bermejo-Pareja; María José Medrano; Elan D Louis; Julián Benito-León
Journal:  Gerontology       Date:  2014-12-06       Impact factor: 5.140

8.  Views of older persons with multiple morbidities on competing outcomes and clinical decision-making.

Authors:  Terri R Fried; Sarah McGraw; Joseph V Agostini; Mary E Tinetti
Journal:  J Am Geriatr Soc       Date:  2008-09-02       Impact factor: 5.562

Review 9.  Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future.

Authors:  Eiran Z Gorodeski; Parag Goyal; Scott L Hummel; Ashok Krishnaswami; Sarah J Goodlin; Linda L Hart; Daniel E Forman; Nanette K Wenger; James N Kirkpatrick; Karen P Alexander
Journal:  J Am Coll Cardiol       Date:  2018-05-01       Impact factor: 24.094

10.  Perspectives on Implementing a Multidomain Approach to Caring for Older Adults With Heart Failure.

Authors:  Parag Goyal; Eiran Z Gorodeski; Kelsey M Flint; Deena S Goldwater; John A Dodson; Jonathan Afilalo; Mathew S Maurer; Michael W Rich; Karen P Alexander; Scott L Hummel
Journal:  J Am Geriatr Soc       Date:  2019-10-18       Impact factor: 5.562

View more
  19 in total

1.  Co-morbidity and Polypharmacy Burden Among Adults with Self-Reported Heart Failure Overall, and by Gender and Race/Ethnicity: NHANES 2007-2018.

Authors:  Alexander R Zheutlin; Alexander Chaitoff; Joshua D Niforatos
Journal:  J Gen Intern Med       Date:  2022-06-14       Impact factor: 5.128

2.  PathoClock and PhysioClock in mice recapitulate human multimorbidity and heterogeneous aging.

Authors:  Shabnam Salimi; Christina Pettan-Brewer; Warren Ladiges
Journal:  Aging Pathobiol Ther       Date:  2021-12-31

3.  Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.

Authors:  Masatoshi Minamisawa; Brian Claggett; Kota Suzuki; Sheila M Hegde; Amil M Shah; Akshay S Desai; Eldrin F Lewis; Sanjiv J Shah; Nancy K Sweitzer; James C Fang; Inder S Anand; Eileen O'Meara; Jean-Lucien Rouleau; Bertram Pitt; Marc A Pfeffer; Scott D Solomon; Orly Vardeny
Journal:  Circ Heart Fail       Date:  2021-10-22       Impact factor: 8.790

Review 4.  Frailty in older adults with heart disease.

Authors:  Peter Dovjak
Journal:  Z Gerontol Geriatr       Date:  2022-06-20       Impact factor: 1.292

5.  Could a Low-Dose Diuretic Polypill Improve Outcomes in Heart Failure With Preserved Ejection Fraction?

Authors:  Sadiya S Khan; Mark D Huffman; Sanjiv J Shah
Journal:  Circ Heart Fail       Date:  2021-03-05       Impact factor: 8.790

6.  Association Between β-Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry.

Authors:  Markus Meyer; Jeanne Du Fay Lavallaz; Lina Benson; Gianluigi Savarese; Ulf Dahlström; Lars H Lund
Journal:  J Card Fail       Date:  2021-05-08       Impact factor: 5.712

7.  Response by Unlu et al to Letter Regarding Article, "Polypharmacy in Older Adults Hospitalized for Heart Failure".

Authors:  Ozan Unlu; Emily B Levitan; Mathew S Maurer; Monika M Safford; Mark S Lachs; Parag Goyal
Journal:  Circ Heart Fail       Date:  2021-03-12       Impact factor: 8.790

8.  Characterizing Sex Differences in Physical Frailty Phenotypes in Heart Failure.

Authors:  Quin E Denfeld; Beth A Habecker; S Albert Camacho; Mary Roberts Davis; Nandita Gupta; Shirin O Hiatt; Mary E Medysky; Jonathan Q Purnell; Kerri Winters-Stone; Christopher S Lee
Journal:  Circ Heart Fail       Date:  2021-08-25       Impact factor: 10.447

9.  Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction.

Authors:  Pedram Navid; Linh Nguyen; Diana Jaber; Kate Zarzuela; Mahad Musse; Marcos Lu Wang; Tatiana Requijo; Elissa Kozlov; Ruth M Masterson Creber; Sarah N Hilmer; Mark Lachs; Parag Goyal
Journal:  J Am Geriatr Soc       Date:  2021-05-12       Impact factor: 7.538

Review 10.  Polypharmacy definition and prevalence in heart failure: a systematic review.

Authors:  Janine Beezer; Manal Al Hatrushi; Andy Husband; Amanj Kurdi; Paul Forsyth
Journal:  Heart Fail Rev       Date:  2021-07-02       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.